rubidium has been researched along with B-Cell Chronic Lymphocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shemon, AN; Sluyter, R; Wiley, JS | 1 |
| Chen, R; Jamieson, GP; Wiley, JS; Wiley, MJ | 1 |
2 other study(ies) available for rubidium and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Rottlerin inhibits P2X(7) receptor-stimulated phospholipase D activity in chronic lymphocytic leukaemia B-lymphocytes.
Topics: Acetophenones; Adenosine Triphosphate; B-Lymphocytes; Benzopyrans; Cell Line, Tumor; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phospholipase D; Polymorphism, Genetic; Protein Isoforms; Protein Kinase C; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Rubidium | 2007 |
The ATP4- receptor-operated ion channel of human lymphocytes: inhibition of ion fluxes by amiloride analogs and by extracellular sodium ions.
Topics: Adenosine; Adenosine Triphosphate; Amiloride; Calcium; Cell Membrane Permeability; Cytosol; In Vitro Techniques; Ion Channels; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Ribonucleotides; Rubidium; Sodium | 1992 |